Business
Jaguar Health Provides Updates on Investigator-Initiated Trials of Crofelemer (Mytesi)
Company shares updates on investigator-initiated trials of crofelemer (Mytesi®), a novel FDA-approved plant-based oral prescription medicineSAN FRANCISCO, CA
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Company shares updates on investigator-initiated trials of crofelemer (Mytesi®), a novel FDA-approved plant-based oral prescription medicineSAN FRANCISCO, CA / ACCESSWIRE / August 19, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today provided updates regarding ongoing investigator-initiated trials in non-HIV patient populations of crofelemer (Mytesi®), the novel FDA-approved plant-based oral drug developed and marketed by Jaguar's wholly-owned subsidiary, Napo Pharmaceuticals, Inc.Updates Regarding Investigator-Initiated Trials: Chronic Idiopathic Diarrhea in Non-HIV Adult PatientsYield of Diagnostic Tests and Management of Crofelemer for Chronic Idiopathic Diarrhea in Non-HIV Patients: A Pilot StudyFollowing COVID-related delays, this single-center clinical research study in adult non-HIV patients at The University of Texas Health Science Center at Houston (UTH) has started enrolling. Full enrollment is expected to be reached by the end of 2020, and the study results are expected to be available by mid to late 2021.Chronic idiopathic diarrhea is a common complaint of patients presenting to family practitioners and internists and is one of the most common reasons for referral to gastroenterologists. It is estimated that the prevalence of chronic idiopathic diarrhea in developed countries (including the U.S.) is approximately 3-5%. It has a significant negative effect on health-related quality of life and causes a high economic burden on patients and society. The American Gastroenterological Association Burden of Illness study (2012) showed that the estimated annual direct and indirect costs associated with chronic idiopathic diarrhea are up to $524 million per year and $136 million per year, respectively.Functional Diarrhea in Non-HIV Adult PatientsA randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of crofelemer in subjects with functional diarrheaThis investigator-initiated study will be conducted at a single center at Beth Israel Deaconess Medical Center, a Harvard Medical School institution in Boston. This study is expected to initiate enrollment of patients in the fourth quarter of 2020, and topline results are expected to be available in fourth quarter of 2021.Diarrhea in HER2-positive Breast Cancer PatientsHALT-D: Diarrhea Prevention and Prophylaxis with Crofelemer in HER2 ...